Hepatitis B



TDF Medicine to Prevent Mother to Child Transmission of Hepatitis B


Condition:   Hepatitis B
Intervention:   Drug: Tenofovir Disoproxil Fumarate
Sponsor:   University of Oxford
Not yet recruiting - verified May 2017


A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B


Condition:   Chronic Hepatitis B
Intervention:  
Sponsors:   Beijing Friendship Hospital;   Beijing YouAn Hospital;   First Hospital of Jilin University;   Henan Provincial Hospital;   Beijing Ditan Hospital;   First Affiliated Hospital of Xinjiang Medical University;   The First Hospital of Lanzhou University;   The Second Affiliated Hospital of Chongqing Medical University;   West China Hospital;   Taiyuan No.3 Hospital;   Hebei Medical University Third Hospital;   Shengjing Hospital;   Tianjin Third Central Hospital;   Peking University First Hospital;   LanZhou University;   Peking Union Medical College Hospital;   The Affiliated Hospital Of Southwest Medical University;   Shanghai Public Health Clinical Center;   Ruijin Hospital;   First Affiliated Hospital Xi'an Jiaotong University;   Xiangya Hospital of Central South University;   Beijing Tiantan Hospital,Capital Medical University;   Wuhan University;   The First Affiliated Hospital of Kunming Medical College;   The Affiliated Hospital of Xuzhou Medical University;   The Affiliated Hospital of Yanbian University;   First Affiliated Hospital of Chongqing Medical University;   The Fouth Hospital of Qinghai province;   Affiliated Hospital of Weifang Medical University;   Hunan Provincial People's Hospital;   The Second Hospital of Hebei Medical University;   Xixi Hospital of Hangzhou;   General Hospital of Ningxia Medical University;   Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology;   Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital;   Peking University People's Hospital;   Nanfang Hospital of Southern Medical University;   The Affiliated Hospital Of Guizhou Medical University;   Guizhou Provincial People's Hospital;   Hainan General Hospital;   The Second Hospital of Shandong University;   The First Affiliated Hospital of Shanxi Medical University;   Fifth Hospital of Shijiazhuang City;   Yan'an University Affiliated Hospital;   Infectious Disease Hospital of Wuhai;   Affiliated Hospital, Logistics University of People's Armed Police Force;   People's Hospital of Changji Hui Autonomous Prefecture,Xinjiang
Recruiting - verified June 2012


Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus


Condition:   Hepatitis B
Intervention:   Drug: Tenofovir Disoproxil Fumarate
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Thrasher Research Fund;   Shoklo Malaria Research Unit;   Chiang Mai University
Not yet recruiting - verified February 2017


The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B


Condition:   Chronic Hepatitis B
Interventions:   Drug: Metacavir Enteric-coated Capsules 80mg;   Drug: Metacavir Enteric-coated Capsules 160mg;   Drug: Metacavir Enteric-coated Capsules 320mg;   Drug: Metacavir Enteric-coated Capsules Placebo 240mg;   Drug: Metacavir Enteric-coated Capsules Placebo 160mg;   Drug: Metacavir Enteric-coated Capsules Placebo 320mg;   Drug: Adefovir Dipivoxil Capsule10mg;   Drug: Adefovir Dipivoxil Capsule Placebo 10mg
Sponsor:   Guangzhou Yipinhong Pharmaceutical CO.,LTD
Recruiting - verified August 2016


The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg


Condition:   Chronic Hepatitis B
Intervention:   Drug: peginterferon alfa
Sponsors:   Third Affiliated Hospital, Sun Yat-Sen University;   Peking University;   Huazhong University of Science and Technology;   Nanchang University;   Huizhou Municipal Central Hospital;   First People's Hospital, Shunde China;   Shenzhen Third People's Hospital;   First People's Hospital of Foshan;   Tang-Du Hospital;   The First Affiliated Hospital of Kunming Medical College;   Yuebei People's Hospital
Active, not recruiting - verified September 2016


Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders


Condition:   Hepatitis B
Interventions:   Biological: HBVaxPro;   Biological: HBAI20
Sponsors:   Maastricht University Medical Center;   CyTuVax
Completed - verified September 2016


Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B


Condition:   Chronic Hepatitis B
Intervention:   Drug: Peginterferon alfa-2a
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2, 2017


This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age


Condition:   Hepatitis B
Intervention:   Other: Data collection
Sponsor:   GlaxoSmithKline
Completed - verified July 2016


Hepatitis B Booster Study in Adolescence


Condition:   Hepatitis B
Intervention:  
Sponsors:   University of British Columbia;   Canadian Immunization Research Network;   Canadian Institutes of Health Research (CIHR)
Completed - verified May 2016


A Study of the Immune Response to Heplisav in Healthy Older Adults


Condition:   Hepatitis B
Intervention:   Biological: HEPLISAV
Sponsors:   Dynavax Technologies Corporation;   Baylor Research Institute
Completed - verified March 2017


Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen


Condition:   Chronic Hepatitis B
Intervention:   Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors:   Johannes Gutenberg University Mainz;   Roche Pharma AG
Active, not recruiting - verified March 2017


Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B


Condition:   Hepatitis B
Intervention:   Drug: Entecavir and peginterferon
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Pittsburgh
Completed - verified March 2017


Duration of Long-term Immunity After Hepatitis B Virus Immunization


Condition:   Hepatitis B
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 24, 2016


Increasing Hepatitis B Screening Among Korean Church Attendees


Condition:   Hepatitis B
Intervention:   Behavioral: Educational Small Group Session
Sponsors:   University of California, Los Angeles;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Completed - verified November 2016


Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine


Condition:   Hepatitis B
Intervention:   Biological: Engerix™-B
Sponsor:   GlaxoSmithKline
Completed - verified November 2016


Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.


Condition:   Hepatitis B Vaccine
Intervention:   Biological: Engerix™-B Kinder
Sponsor:   GlaxoSmithKline
Completed - verified November 2016


Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.


Condition:   Hepatitis B
Intervention:   Biological: Engerix™-B
Sponsor:   GlaxoSmithKline
Completed - verified November 2016


Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)


Condition:   Hepatitis B Virus Infection
Interventions:   Biological: Comparator: modified process hepatitis B vaccine;   Biological: Comparator: ENGERIX-B™
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib


Condition:   Hepatitis B
Intervention:   Biological: hepatitis B vaccine
Sponsor:   GlaxoSmithKline
Completed - verified October 2016


Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib


Condition:   Hepatitis B
Intervention:   Biological: hepatitis B vaccine
Sponsor:   GlaxoSmithKline
Completed - verified October 2016


Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)


Condition:   Hepatitis B
Intervention:   Procedure: Blood sampling
Sponsor:   GlaxoSmithKline
Completed - verified October 2016


LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers


Condition:   Hepatitis B
Interventions:   Biological: Engerix™ -B;   Biological: Hepatitis B immunoglobulin (HBIg)
Sponsor:   GlaxoSmithKline
Completed - verified October 2016


Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers


Condition:   Hepatitis B
Intervention:   Biological: Engerix™-B
Sponsor:   GlaxoSmithKline
Completed - verified November 2016


Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)


Condition:   Hepatitis B
Interventions:   Drug: Lamivudine;   Biological: Recombinant hepatitis B surface antigen
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   GlaxoSmithKline
Terminated - verified March 2008


Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths


Condition:   Hepatitis B
Interventions:   Biological: Recombivax;   Biological: Twinrix
Sponsors:   University of North Carolina, Chapel Hill;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified March 2016

Refine Your Search Advanced Search